Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment

S Ataei-Nakhaei, K Aryana, SM Mostafavi… - … of Endocrinology and …, 2022 - SciELO Brasil
S Ataei-Nakhaei, K Aryana, SM Mostafavi, HM Kosari, M Esmatinia, A Aghaee
Archives of Endocrinology and Metabolism, 2022SciELO Brasil
SUMMARY A 59-year-old woman with follicular thyroid carcinoma underwent total
thyroidectomy followed by radioiodine treatment. Following treatment, the whole-body scan
did not show any abnormal radioiodine uptake. However, during the follow-up, the serum
thyroglobulin (Tg) value increased without detectable thyroglobulin-antibodies. We
performed a Ga-68 DOTA-TATE PET/CT showing a sternal lesion and several lung nodules
with high somatostatin receptor density. Also, on the next day, FDG PET/CT was performed …
Summary
A 59-year-old woman with follicular thyroid carcinoma underwent total thyroidectomy followed by radioiodine treatment. Following treatment, the whole-body scan did not show any abnormal radioiodine uptake. However, during the follow-up, the serum thyroglobulin (Tg) value increased without detectable thyroglobulin-antibodies. We performed a Ga-68 DOTA-TATE PET/CT showing a sternal lesion and several lung nodules with high somatostatin receptor density. Also, on the next day, FDG PET/CT was performed, which confirmed the findings. Considering the high levels of somatostatin receptor expression in such metastases, we planned lu177 DOTA-TATE therapy. After two cycles of lu177 DOTA-TATE injection, serum thyroglobulin significantly dropped, and she claimed that her sternal pain and dyspnea were much better. This was the case of a patient suffering from iodine-refractory follicular thyroid carcinoma, with somatostatin-receptor expression, treated with 177Lu-DOTA-TATE, showing a significant response.
SciELO Brasil
以上显示的是最相近的搜索结果。 查看全部搜索结果